19:15 , Jun 22, 2018 |  BC Week In Review  |  Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced...
04:46 , Jun 21, 2018 |  BC Extra  |  Financial News

Four companies in IPO quintet post first-day gains

Four of the five biopharmas that priced IPOs late Wednesday posted gains on Thursday. Cell therapy company Avrobio Inc. (NASDAQ:AVRO) had the biggest first-day bump, climbing $12.20 (64%) to $31.20, while three others posted double-digit...
19:14 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Avrobio proposes $86.3M NASDAQ IPO

Avrobio Inc. (Cambridge, Mass.) proposed on May 25 to raise $86.3 million in an IPO underwritten by Morgan Stanley, Cowen, Wells Fargo and Wedbush PacGrow. In February, the cell therapy company raised $60 million in a...
22:08 , May 25, 2018 |  BC Extra  |  Financial News

Eidos, Avrobio propose NASDAQ IPOs

Eidos Therapeutics Inc. (Palo Alto, Calif.) and Avrobio Inc. (Cambridge, Mass.) proposed NASDAQ IPOs on Friday. Eidos proposed to raise $115 million in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and Barclays. Last month,...
15:38 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Japan approvals include Hemlibra, Shingrix Galafold

Japan approved a basket of drugs including hemophilia drug Hemlibra emicizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), shingles vaccine Shingrix from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Fabry's disease drug Galafold migalastat from Amicus Therapeutics Inc....
22:09 , Mar 23, 2018 |  BC Extra  |  Company News

Japan approvals include Hemlibra, Shingrix, Galafold

Japan approved a basket of drugs including hemophilia drug Hemlibra emicizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), shingles vaccine Shingrix from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Fabry's disease drug Galafold migalastat from Amicus Therapeutics Inc....
15:25 , Feb 23, 2018 |  BC Week In Review  |  Financial News

Amicus raises $300M in bumped-up follow-on

Amicus Therapeutics Inc. (NASDAQ:FOLD) raised $300 million on Feb. 15 through the sale of 19.4 million shares at $15.50 in an upsized follow-on underwritten by J.P. Morgan, Goldman Sachs, Cowen, Leerink and BofA Merrill Lynch....
18:08 , Feb 16, 2018 |  BC Extra  |  Financial News

Amicus raises $300M in bumped-up follow-on

Amicus Therapeutics Inc. (NASDAQ:FOLD) raised $300 million through the sale of 19.4 million shares at $15.50 in an upsized follow-on underwritten by J.P. Morgan, Goldman Sachs, Cowen, Leerink and BofA Merrill Lynch. The price is...
13:04 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Priority Review for Amicus' migalastat

FDA accepted and granted Priority Review to an NDA from Amicus Therapeutics Inc. (NASDAQ:FOLD) for migalastat (AT1001) to treat Fabry's disease in patients 16 years and older who have amenable mutations. The PDUFA date is...
22:06 , Feb 12, 2018 |  BC Extra  |  Company News

Priority Review for Amicus' migalastat

FDA accepted and granted Priority Review to an NDA from Amicus Therapeutics Inc. (NASDAQ:FOLD) for migalastat (AT1001) to treat Fabry's disease in patients 16 years and older who have amenable mutations. The PDUFA date is...